Inhalable Drug Delivery device is meant to administer medications that are to be inhaled deeply into the lungs.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Inhalable Drug Delivery Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Inhalable Drug Delivery Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Inhalable Drug Delivery Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acorda Therapeutics Inc
- Actervis GmbH
- Aerami Therapeutics Inc
- Aerophase Inc
- Alexza Pharmaceuticals Inc
- Atossa Therapeutics Inc
- Baxter International Inc
- Bellerophon Therapeutics Inc
- Breath Therapeutics Holding BV
- California Northstate University College of Medicine
- Canigma A.L LTD
- Edixomed Ltd
- Engage Therapeutics Inc
- iDTx Systems, Inc.
- Impel NeuroPharma Inc
- Inhalation Sciences Sweden AB
- InhaleRx Ltd
- Invero Pharma LLC
- Jupiter Research LLC
- Kanabo Research Ltd
- Mallinckrodt Plc
- Medical Developments International Ltd
- Medspray BV
- Monash University
- Nemera La Verpilliere
- Next Safety, Inc.
- Nobilis Therapeutics Inc
- OncoSec Medical Inc
- Parnell Pharmaceuticals Inc
- Pharmosa Biopharm Inc
- Rhinomed Limited
- Rutgers Cancer Institute of New Jersey
- Sandoz International GmbH
- Seng Vital International GmbH
- Shenzhen Smoore Technology Ltd
- Technology Commercialization Partners LLC
- Tetra Bio-Pharma Inc
- Teva Pharmaceutical Industries Ltd
- Texas Tech University Health Sciences Center
- Third Pole Inc
- Tiziana Life Sciences PLC
- Torrent Pharmaceuticals Ltd
- University Hospital Southampton NHS Foundation Trust
- University of Texas Health Science Center at Houston
- Vectura Group Plc
- Veoli Ltd
- Vero Biotech LLC
- Via Therapeutics LLC
- Virpax Pharmaceuticals Inc
- VistaGen Therapeutics Inc
- VitalMIST
- Windtree Therapeutics Inc